Landmark Bio and Galapagos have signed a multi-year strategic manufacturing agreement for the manufacture of the latter's oncology chimeric antigen receptor (CAR) T-cell therapy clinical programmes at the point of care.

The details of the agreement's financial terms were not revealed.

Landmark Bio will manufacture clinical trial batches of Galapagos' CAR-T cell therapies for haematology-oncology in compliance with Good Manufacturing Practice standards in the Boston metropolitan area, US.

The manufacturing agreement seeks to implement Galapagos' decentralised CAR-T manufacturing model, which allows clinicians to administer CAR T-cells within a median of seven days of leukapheresis, overcoming key limitations of existing CAR-T treatments.

Landmark Bio CEO Ran Zheng stated: “We are excited to partner with Galapagos to support their CAR-T clinical development programmes in the US.

“This strategic manufacturing collaboration is a testament to our expertise in cell and gene therapy manufacturing and underscores our commitment to bring more life-saving therapies to patients faster.”

Landmark Bio operates a 44,000ft² fully integrated development and manufacturing facility, which offers laboratory space for translational research early development, process and analytical development, and technology innovation.

The biomanufacturing area includes nine cleanrooms for cell therapies, genome editing, viral vector, mRNA, lipid nanoparticle production, fill and finish and in-house quality control testing.

The company also offers wraparound services such as drug development, regulatory consulting and programme management.